Valuation: LB Pharmaceuticals Inc

Market Cap 915M 803M 740M 693M 1.3B 86.35B 1.33B 8.89B 3.44B 42.68B 3.44B 3.36B 148B P/E 2026 *
-9x
P/E 2027 * -7.29x
Enterprise Value 626M 549M 506M 474M 888M 59.06B 907M 6.08B 2.35B 29.19B 2.35B 2.3B 101B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day+2.97%
1 week+6.40%
Current month+14.12%
1 month+12.67%
3 months+30.13%
6 months+48.26%
Current year+43.40%
1 week 29.54
Extreme 29.54
32.16
1 month 26.37
Extreme 26.37
32.16
Current year 18.43
Extreme 18.43
33.47
1 year 13.36
Extreme 13.36
33.47
3 years 13.36
Extreme 13.36
33.47
5 years 13.36
Extreme 13.36
33.47
10 years 13.36
Extreme 13.36
33.47
Manager TitleAgeSince
Chief Executive Officer 53 2024-11-18
Director of Finance/CFO 55 2016-02-29
Chief Tech/Sci/R&D Officer 59 2025-01-31
Director TitleAgeSince
Director/Board Member 76 2019-06-30
Director/Board Member 53 2023-07-31
Director/Board Member 53 2024-11-18
Date Insider Type Main position Quantity % Market Cap.
06-02Free

Chairman

10,000 0.0446%
06-02Free

Director

10,000 0.0446%
06-02Free

Director

10,000 0.0446%
Change 5-day change 1-year change 3-year change Capi.($)
+2.97%+6.40% - - 915M
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +0.40%+4.94%+42.26%+128.88% 22.72B
Weighted average by Cap. +0.27%+5.14%+48.50%+120.17%

Financials

2026 *2027 *
Net sales - -
Net income -105M -92.36M -85.14M -79.71M -149M -9.94B -153M -1.02B -396M -4.91B -396M -387M -17.03B -162M -142M -131M -122M -230M -15.27B -234M -1.57B -609M -7.55B -608M -595M -26.17B
Net Debt -289M -254M -234M -219M -410M -27.29B -419M -2.81B -1.09B -13.49B -1.09B -1.06B -46.77B -450M -395M -364M -341M -639M -42.46B -652M -4.37B -1.69B -20.98B -1.69B -1.65B -72.76B
Logo LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Employees
35
Date Price Change Volume
26-06-26 US$31.92 +2.97% 1,413,712
26-06-25 US$31.00 +1.71% 213,094
26-06-24 US$30.48 -0.39% 295,027
26-06-23 US$30.60 +2.44% 824,513
26-06-22 US$29.87 -0.43% 345,039
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
31.92USD
Average target price
45.00USD
Spread / Average Target
+40.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LBRX Stock